Induction of drug induced tolerance in mice and application for large animals

小鼠药物耐受的诱导及其在大型动物中的应用

• 批准号: 07671312
• 负责人: TOMITA Yukihiro
• 金额: $ 1.6万
• 依托单位: Kyushu University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 1995
• 资助国家: 日本
• 起止时间: 1995 至 1996
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-07671312/
• 关键词: Cyclophosphamide; drug induced tolerance; Major Histocompatibility (MHC); chimera; clonal deletion; Cyclophosphamide; キメリズム; 薬剤誘導性免疫寛容; デストラクション; 皮膚移植; 生着延長

From analysis performed in 1995, the following results were obtained. 1) Chimerism was induced only in lymphocytes, and wasn't induced in bone marrow level. 2) In the combination of B10D2 and B10 (MHC alone disparate), clonal destruction was observed, but the induction of chimerism was transient, and 3) skin graft survival prolongation and duration of chimeric state had significnat relationship.From 1996, we started the analysis of our new protochol (SC+CP+Busulfan+Bone marrow cells protochol) to break through the MHC obstacle. We got very encouraging data that permanent chimerism and skingraft survaival were observed by using busulfan with our traditional CP induced tolorance protochol.The final goal that we want to achive is to induce tolerance only by drugs in large animals. And we think our new data is going to be a greater success.

根据 1995 年进行的分析，获得了以下结果。 1)仅在淋巴细胞中诱导嵌合，在骨髓水平中不诱导嵌合。 2）在B10D2和B10组合（MHC单独不同）时，观察到克隆破坏，但嵌合状态的诱导是短暂的，3）皮片存活时间延长和嵌合状态持续时间有显着关系。从1996年开始，我们开始分析我们的新方案（SC+CP+白消安+骨髓细胞方案）以突破MHC障碍。我们得到了非常令人鼓舞的数据，即通过使用白消安与我们传统的 CP 诱导耐受方案观察到永久嵌合和皮肤移植存活。我们想要实现的最终目标是仅通过药物在大型动物中诱导耐受。我们认为我们的新数据将会取得更大的成功。